Although it was adequately assessed in Takeda Pharmaceutical Co. Ltd.’s Entyvio (vedolizumab) development program and no cases were discovered, the risk of progressive multifocal leukoencephalopathy still lingers enough to require a potentially extensive post-marketing risk management plan, an FDA advisory committee concluded.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?